December 13, 2024
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. The proceeds from the Directed Share Issue are intended to be used to advance key projects that reinforce Magle Group’s position in innovative medical solutions and support the group’s ongoing structural and organisational changes following recent mergers.
» Read moreDecember 2, 2024
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development.
» Read moreNovember 22, 2024
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
» Read moreNovember 18, 2024
Agtira offers its Farming as a Service (FaaS) approach to food chains, shops and other stakeholders. This means that Agtira invests, builds and then operates its farming systems for the production of a range of vegetables and fish species, either by itself or together with a third party, while the store or chain undertakes to buy the entire volume produced over a certain contractual period at predetermined prices. What Agtira's farming systems have in common is that they produce food with low water consumption in closed environments, with no emissions to the local environment or need for agricultural land. Growing in urban environments also means reducing the need for transportation and reducing waste.
» Read moreNovember 5, 2024
Q-linea is an innovative infection diagnostics company that develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's first product, ASTar, has in completed studies shown to be able to determine which antibiotics are effective against an infection, so-called AST analysis, significantly faster than other methods. ASTar was launched on the European market in the autumn of 2021 and after the Company received market approval for the US market on April 26, 2024, ASTar has also been launched in the US.
» Read moreOctober 10, 2024
Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has successfully been applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application.
» Read moreSeptember 25, 2024
Gaming Corps AB is a development company that operates in the global digital gaming market by developing casino games within iGaming. The Company was founded in 2014 and has been listed on Nasdaq First North Growth Market since 2015. Gaming Corps is based in Uppsala and has wholly owned subsidiaries in Malta, from which employees work remotely and where all game development takes place. Operations focus on several categories of casino games: Casino Slots, Table Games, Multiplier Games, Mine Games and Smash4cash. The Company works mainly with two business models, the first of which consists of the development of non-exclusive games that can be offered to more than one operator. The second business model relates to the development of tailor-made and/or exclusive games for individual operators, as well as various levels of branding and theme customization based on their needs.
» Read moreJune 24, 2024
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada.
» Read moreJune 17, 2024
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. pK Chemicals, headquartered in Denmark, is a leading player in the global pharmaceutical and medico sectors. Known for its production of technical Dextran and Dextran Derivatives, pK Chemicals has 65 employees and operates two manufacturing sites in Denmark. In 2023, pK Chemicals reported a gross profit of approximately SEK 116 million, with a profit from operating activities of approximately SEK 17 million.
» Read moreJune 14, 2024
Vator Securities acts as the Listing Agent for Tingsvalvet Fastighets AB during the listing on Nasdaq First North Growth Market. Tingsvalvet is a cash flow-driven real estate company focused on commercial properties with high yields, particularly in strong local locations in central Sweden. As of March 31, 2024, the property value amounted to approximately 1.9 billion SEK. The company acquires, refines, and develops high-yield commercial properties and owns easy-to-manage properties with strong cash flows and stable tenants. Tingsvalvet has a diversified property portfolio with an average contract length of 7.9 years.
» Read moreJune 13, 2024
Yabie is a fast-growing SaaS company that offers products and services that make everyday life easier for business owners. Since 2017, Yabie has developed an ecosystem of user-friendly checkout and payment solutions used by thousands of businesses in Sweden, from the pizzeria on the corner to IKEA. Through innovation, scalability and a clear product focus, Yabie is gaining market share at a rapid pace. Yabie has developed an ecosystem of services for business customers to make it easier to get paid and drive their business forward. Yabie offers an innovative and mobile checkout and payment solution for a broad target group, from small businesses up to larger international corporate customers such as IKEA.
» Read moreMay 21, 2024
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
» Read moreMay 3, 2024
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies.
» Read moreApril 19, 2024
Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
» Read moreApril 5, 2024
SciBase is a global medical technology company specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to increase diagnostic accuracy and ensure the prevention of skin diseases. SciBase's commitment is to minimize patient suffering, enable physicians to improve and save lives through rapid detection and intervention, and reduce healthcare costs.
» Read moreMarch 22, 2024
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.
» Read more